OK. Well I did not invest in CVM. Obviously the same nonsensical spin. No two trials are “doppelgängers”. This is nonsense.
As for whether it succeeded or failed, no idea but many seem to think it has a likelihood of approval. But they are not “doppelgängers”. That is a bunch of huey.
The game is up here because we know the game. The company appears to know the game. Many companies stupidly proceed thinking that results will convince the gamers of stock that they are wrong, but defining reality against commercial statements is an easy thing when you have writers posing as journalists who will write pieces to substantiate the claims of shorts, for whatever reason. But the reality is, their opinions do not matter in the context of scientific articles and journals. And that is the key difference with CVM.
They went the commercial announcement route. NWBO is going the journal route. So you are absolutely wrong in your comparison. And if it were as you indicate, there is no way in hell they would go the journal route first or even in the middle or last.
Market Data 
Markets 
AI
